Sleep Disorders Trial, Recruiting NCT07533799 Sponsor: Skane University Hospital Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT07533799
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with a sleep condition called RBD (REM Sleep Behaviour Disorder):

  • A sleep study has confirmed the RBD diagnosis according to recognised medical guidelines
  • The person does not have a diagnosis of Parkinson's disease
  • The person is aged between 50 and 100 years old
  • Women under 55 who have not yet reached menopause will need to take a pregnancy test before certain scan procedures
  • The person is able to give informed consent to take part
  • The person speaks and understands Swedish well enough to complete study information and thinking/memory tests without an interpreter

People with early Parkinson's disease:

  • The person has been diagnosed with Parkinson's disease according to recognised medical guidelines
  • The person is either not yet on any Parkinson's treatment, or has been on treatment for no more than 3 years
  • The person is aged between 50 and 100 years old
  • Women under 55 who have not yet reached menopause will need to take a pregnancy test before certain scan procedures
  • The person is able to give informed consent to take part
  • The person speaks and understands Swedish fluently

Healthy volunteers (control group):

  • The person is aged between 50 and 100 years old
  • Women under 55 who have not yet reached menopause will need to take a pregnancy test before certain scan procedures
  • The person does not have a diagnosis of Parkinson's disease or any other significant neurological condition
  • The person does not have a diagnosis of RBD
  • The person is able to give informed consent to take part
  • The person speaks and understands Swedish fluently

Who may not be able to join:

  • People with a history of serious or repeated head injuries, stroke, significant ongoing physical illness, or an unstable medical condition
  • People with a history of severe and unstable depression, schizophrenia, schizoaffective disorder, or bipolar disorder
  • People with significant damage to the small blood vessels in the white matter of the brain (confirm with trial site)
  • People for whom MRI or PET scans are not medically safe or suitable
  • People in the early Parkinson's disease group whose brain dopamine transporter scan result comes back as normal

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Erik Stomrud, MD, PhD, Skane University Hospital and Lund University

Phone: +46 40 33 10 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Skane University Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2021
Est. completion
1 June 2033

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Longitudinal Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS); Longitudinal Changes in Mini-Mental State Examination (MMSE); Time to phenoconversion from iRBD to manifest parkinsonian disorders

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov